CDSCO Panel Approves Updated Prescribing Information for AstraZeneca's Rosuvastatin (Crestor)

Written By : Dr. Divya Colin |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-06-08T12:43:07+05:30 | Updated On 8 Jun 2025 12:43 PM IST

CDSCO Panel Clears AstraZenecas Datopotamab for Breast Cancer, Seeks Phase IV Trial

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval for the updated Prescribing Information of Rosuvastatin Calcium Tablets IP 5mg, 10mg, 20mg, and 40mg (Crestor), marketed by AstraZeneca Pharma India Limited.

The decision came following AstraZeneca’s presentation of proposed updates to Version 6 and 7 of the drug’s Prescribing Information before the expert panel during the SEC (Cardiovascular) meeting held on April 9, 2025.

Rosuvastatin belongs to a class of drugs known as HMG-CoA reductase inhibitors (statins). It works by inhibiting an enzyme responsible for cholesterol production in the liver, thereby lowering LDL (bad cholesterol) and triglycerides, while increasing HDL (good cholesterol). The medication is commonly prescribed to prevent cardiovascular events such as heart attacks and strokes in at-risk patients.

After detailed deliberation, the committee recommended approval of the updated prescribing details as presented by the company.

Also Read: CDSCO Panel Approves BE Study for Alkem's Dapagliflozin, Pioglitazone, Metformin FDC, Seeks Revised Phase III Plan

astrazenecaprescription drugseccdscorosuvastatin calciumcrestorstatincholesterol drugcardiovascular sec meetingcrestor prescribing infolipid lowering drug

Dr. Divya Colin

Doctor of Pharmacy

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751